Topical Analgesia Post-Haemorrhoidectomy
Primary Purpose
Hemorrhoid Pain, Hemorrhoids
Status
Completed
Phase
Phase 2
Locations
New Zealand
Study Type
Interventional
Intervention
Metronidazole cream
Metronidazole and Diltiazem cream
Metronidazole and Lidocaine cream
Metronidazole, Diltiazem and Lidocaine cream
Sponsored by
About this trial
This is an interventional treatment trial for Hemorrhoid Pain
Eligibility Criteria
Inclusion Criteria:
- Age ≥16
- All patients undergoing excisional haemorrhoidectomy
Exclusion Criteria:
- Age <16,
- history of chronic pain,
- drug allergy or idiosyncracies to any actives or excipients in
- cream,
- breastfeeding,
- any medical history which is a contraindication to any of metronidazole, lidocaine, or diltiazem including including:
- sick sinus syndrome,
- atrioventricular block,
- hypotension,
- heart failure and bradycardia.
- concomitant medications which are contraindicated to metronidazole, lidocaine or diltiazem.
- patients already taking diltiazem.
Sites / Locations
- Counties Manukau District Health Board
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Arm Label
Metronidazole
Metronidazole + Diltiazem
Metronidazole + Lignocaine
Metronidazole + Diltiazem + Lignocaine
Arm Description
Group A receiving 10% metronidazole cream
Metronidazole 10% + Diltiazem 2%
Metronidazole 10% + Lignocaine 4%
Metronidazole 10% + Diltiazem 2% + Lignocaine 4%
Outcomes
Primary Outcome Measures
Pain scores
Measured by visual analog scale, 1-10cm, continuous, the higher the score, the worse the pain
Amount of analgesic use
Morphine equivalent amount
Secondary Outcome Measures
Return to work
Day post-operation when the patient returns to work
Pain on bowel motion: Visual Analog Scale
Measured by Visual Analog Scale, continuous 1-10cm, the higher the score, the worse the pain.
Complications
Rates of Bleeding
Re-admission
Rates of Re-admission to hospital,
Repeat Prescription
Rates of Repeat Prescription Requirement
Full Information
NCT ID
NCT04276298
First Posted
February 17, 2020
Last Updated
May 16, 2022
Sponsor
University of Auckland, New Zealand
1. Study Identification
Unique Protocol Identification Number
NCT04276298
Brief Title
Topical Analgesia Post-Haemorrhoidectomy
Official Title
A Prospective, Multicentre, Double-Blinded Randomised Controlled Trial Comparing Topical Metronidazole, Diltiazem and Lidocaine on Post-Operative Pain Following Excisional Haemorrhoidectomy
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
September 1, 2020 (Actual)
Primary Completion Date
February 1, 2022 (Actual)
Study Completion Date
February 1, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Auckland, New Zealand
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Symptomatic haemorrhoids, or piles, have significant effects on quality of life. The treatment for advanced disease is surgical excision (haemorrhoidectomy) which is extremely effective. However, pain following haemorrhoidectomy is known by all to be a miserable experience and current treatment is not very effective. We have formulated a new cream treatment which targets three theorised mechanisms of pain after haemorrhoidectomy. We will test the effectiveness of the treatments with a multi-centred randomised controlled factorial trial with four parallel double-blinded arms containing different combinations of the active agents. The outcomes include pain scores, amount of analgesia required and time to return to work. The results of our study could provide evidence of an effective treatment for post haemorrhoidectomy pain. The treatment may provide considerable benefit to patients undergoing this surgical procedure.
Detailed Description
Study Design: This will be a patient-and-investigator blinded factorial randomised trial with four parallel groups. Participants in all four groups will be instructed to apply cream 3 times a day for 7 days after surgery. A standard analgesia prescription will be provided with laxatives as per routine care. Patients will be provided a questionnaire to complete and return on day 14.
Random Sequence Generation: Computer generated sequence allocating patients to a 1:1:1:1 ratio using permuted block randomisation in blocks of 12.
Allocation Concealment: This randomisation code will be seeded to the pharmacist to who will package and label the cream according to a code. The creams will be indistinguishable to which active ingredient they contain.
Assignment of intervention: Patients will be assigned in order according to the numbering of the cream tubes by the blinded investigator.
Data recording: Data will be recorded on Redcap database.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemorrhoid Pain, Hemorrhoids
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Factorial Assignment
Model Description
Parallel with 1:1:1:1 Allocation.
Masking
ParticipantCare Provider
Masking Description
Double blinded trial, both participant and investigator are blinded.
Allocation
Randomized
Enrollment
192 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Metronidazole
Arm Type
Active Comparator
Arm Description
Group A receiving 10% metronidazole cream
Arm Title
Metronidazole + Diltiazem
Arm Type
Active Comparator
Arm Description
Metronidazole 10% + Diltiazem 2%
Arm Title
Metronidazole + Lignocaine
Arm Type
Active Comparator
Arm Description
Metronidazole 10% + Lignocaine 4%
Arm Title
Metronidazole + Diltiazem + Lignocaine
Arm Type
Active Comparator
Arm Description
Metronidazole 10% + Diltiazem 2% + Lignocaine 4%
Intervention Type
Drug
Intervention Name(s)
Metronidazole cream
Intervention Description
10% metronidazole applied rectally
Intervention Type
Drug
Intervention Name(s)
Metronidazole and Diltiazem cream
Intervention Description
Combination Metronidazole and Diltiazem applied rectally
Intervention Type
Drug
Intervention Name(s)
Metronidazole and Lidocaine cream
Intervention Description
Combination metronidazole and lignocaine applied rectally
Intervention Type
Drug
Intervention Name(s)
Metronidazole, Diltiazem and Lidocaine cream
Intervention Description
Combination of all active agents tested applied rectally
Primary Outcome Measure Information:
Title
Pain scores
Description
Measured by visual analog scale, 1-10cm, continuous, the higher the score, the worse the pain
Time Frame
7 days
Title
Amount of analgesic use
Description
Morphine equivalent amount
Time Frame
7 days
Secondary Outcome Measure Information:
Title
Return to work
Description
Day post-operation when the patient returns to work
Time Frame
14 days
Title
Pain on bowel motion: Visual Analog Scale
Description
Measured by Visual Analog Scale, continuous 1-10cm, the higher the score, the worse the pain.
Time Frame
7 days
Title
Complications
Description
Rates of Bleeding
Time Frame
30 days
Title
Re-admission
Description
Rates of Re-admission to hospital,
Time Frame
30 days
Title
Repeat Prescription
Description
Rates of Repeat Prescription Requirement
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age ≥16
All patients undergoing excisional haemorrhoidectomy
Exclusion Criteria:
Age <16,
history of chronic pain,
drug allergy or idiosyncracies to any actives or excipients in
cream,
breastfeeding,
any medical history which is a contraindication to any of metronidazole, lidocaine, or diltiazem including including:
sick sinus syndrome,
atrioventricular block,
hypotension,
heart failure and bradycardia.
concomitant medications which are contraindicated to metronidazole, lidocaine or diltiazem.
patients already taking diltiazem.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew G Hill, MBChB, MD, EdD, FRACS, FACS
Organizational Affiliation
Counties Manukau Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Counties Manukau District Health Board
City
Auckland
ZIP/Postal Code
1041
Country
New Zealand
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Will be shared when results become available.
IPD Sharing Time Frame
When results are available for 12 months
IPD Sharing Access Criteria
email request
Learn more about this trial
Topical Analgesia Post-Haemorrhoidectomy
We'll reach out to this number within 24 hrs